Weight Watchers (WW) Q4 2025 earnings review
A Tale of Two Businesses: Clinical Surges While Behavioral Bleeds
Weight Watchers ended a turbulent 2025—marked by a Chapter 11 reorganization and the exit from compounded GLP-1s—with a polarizing Q4. Total revenue declined 12% YoY to $163M, dragged down by an ongoing collapse in the legacy Behavioral segment (subscribers down 19%). Conversely, the Clinical segment is accelerating, growing revenue 32% YoY and projecting a massive jump to 200,000 subscribers in 26Q1, aided by the launch of the Wegovy Pill. Despite the successful balance sheet reset and a highly accretive ARPU mix shift, the enterprise is still shrinking. FY26 guidance calls for total revenue of $620-$635M, implying another ~12% YoY contraction, highlighting that Clinical growth is not yet large enough to offset Behavioral attrition.
🐂 Bull Case
Clinical subscribers are guided to reach ~200k in 26Q1 (from 130k in 25Q4). Being a NovoCare Recognized Care Provider for the newly launched Wegovy Pill gives WW a significant structural advantage and acquisition catalyst in the oral GLP-1 market.
The mix shift is highly favorable. Clinical subscribers command an ARPU of $70.82 compared to $16.32 for Behavioral. This dynamic drove overall ARPU up 8% YoY, partially buffering the impact of sheer volume losses.
🐻 Bear Case
The core legacy business lost over 600,000 subscribers YoY. This creates a $50M opening revenue headwind for 2026 that even explosive Clinical growth cannot fully absorb in the near term.
Q4 Adjusted EBITDA margin compressed heavily to 11.1% (from 25.1% in 24Q4) due to front-loaded marketing spend and extra calendar days. Management expects 26Q1 to be highly cash-consumptive as they spend aggressively to establish their medical positioning.
⚖️ Verdict: 🔴
Neutral to Bearish. Management is executing exactly what they must—building an integrated weight health ecosystem and fixing the balance sheet. However, the math is unforgiving: the legacy business is eroding faster than the high-LTV Clinical business can scale. 2026 is openly characterized as a transitional inflection year rather than a return to enterprise growth.
Key Themes
Secular Headwinds Crushing the Core Behavioral Base
The traditional digital and workshop offerings are in structural decline. End of Period Behavioral Subscribers fell to 2.63M, a 19% YoY deceleration. The combination of shifting consumer preference toward medical interventions and brand damage from the recent bankruptcy proceedings continues to severely hamper new member acquisition in this segment.
Wegovy Pill Launch Catalyzing Clinical Surge
After enduring the painful forced transition away from compounded semaglutide in mid-2025, WW's Clinical segment is accelerating again. Q4 subs grew 42% YoY, and Q1 2026 guidance implies a massive sequential jump to 200,000. This is explicitly tied to WW's operational readiness on day one of Novo Nordisk's oral Wegovy launch, tapping into the estimated one-third of consumers who avoid GLP-1s due to injection aversion.
The 'Integrated Care' Efficacy Argument
To combat pure-play telehealth competitors, WW is leaning heavily into clinical data proving the efficacy of combining meds with their legacy behavioral platform. Management cites that members utilizing the GLP-1 Success Program lose 29% more body weight than those using medication alone, and Med+ members with dietitian support are 30% less likely to discontinue treatment. This 'Continuum of Care' is their primary competitive moat.
Marketing Spend Squeezing Near-Term Margins
WW is front-loading 40-45% of its entire 2026 marketing budget into Q1. This concentrated spend is necessary to rebrand the company post-bankruptcy and capitalize on the Wegovy Pill, but it is taking a heavy toll on profitability. Q4 2025 Adjusted EBITDA margin was already compressed to 11.1% (down from 25.1% YoY) due to $10M in early peak-season marketing, and Q1 2026 will see significant cash usage.
Core+ Offering Driving Internal Migration
While overall Behavioral subs are down, the 'Core+' premium tier is showing stabilization and accounts for ~20% of the Behavioral base. More importantly, it is acting as a funnel: approximately 30% of Q4 Clinical signups came directly from existing Behavioral subscribers upgrading. This internal ecosystem migration is crucial for lowering Customer Acquisition Costs (CAC).
Other KPIs
Stable. Following the Chapter 11 emergence in June 2025, WW drastically reduced its crippling $1.4B+ debt load to $465M. The new Term Loan matures in June 2030 (SOFR + 680 bps). This provides essential breathing room, though the credit agreement includes an annual cash sweep for excess cash above $100M starting June 2026.
Accelerating/Improving from 72.3% in Q4 2024. Despite lower total revenue, the mix shift toward the higher-margin Clinical business, coupled with prior $100M run-rate cost-saving actions, is structurally improving the company's gross profitability profile.
Guidance
Decelerating. The midpoint of $627.5M implies an approximate 11.7% YoY decline from 2025's combined revenue of ~$710.6M. Management explicitly attributes this to a $50M opening headwind from the lower 2025 behavioral subscriber base and the loss of ~$20M in revenue from the discontinued compounded semaglutide offering.
Decelerating. Midpoint of $110M represents a significant drop from 2025 levels, reflecting the sheer loss of high-margin behavioral subscription volume and the recalibration of marketing expenses required to reposition the brand.
Decelerating total base, but Clinical is Accelerating. The 2.65M total implies a sequential drop from 2.76M in 25Q4. However, embedded within this is guidance for ~200,000 Clinical subscribers, which would represent a massive 53% sequential jump from 25Q4, proving the success of their Wegovy Pill integration.
Key Questions
Behavioral Floor
With Behavioral subscribers falling another 19% YoY, what are the leading indicators that give you confidence this segment will eventually find a floor, rather than slowly trending toward zero?
H2 2026 Acquisition Strategy
You are front-loading 40-45% of your annual marketing budget into Q1. Given the highly competitive telehealth landscape, how do you plan to sustain Clinical subscriber acquisition in the second half of the year when your share of voice decreases?
Clinical LTV and Retention
As the earliest cohorts of your GLP-1 patients begin to reach their goal weights, what is the data showing regarding their retention? Are they migrating back to Core+, or are they churning off the platform entirely?